ReviewNeural plasticity2025
Schwann Cells and Their Exosomes: Research Progress and Prospect in Spinal Cord Injury.
Review in Neural plasticity, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Spinal cord injury (SCI) is a severe condition that affects the central nervous system (CNS), for which there is currently no effective treatment. Schwann cells (SCs) transplantation for SCI has been well demonstrated in preclinical studies, showing that it can achieve therapeutic goals by improving autonomic function, reducing neuropathic pain, and enhancing limb function through mechanisms such as alleviating inflammation, modulating immunity, and reducing dense scar formation. However, the transplantation of SCs sometimes encounters adverse events, such as low survival rates, significant rejection reactions, limitations on transplantation methods, and the formation of glial scars, all of which severely hinder its clinical application. Meanwhile, SC-derived exosomes (SC-exos) also hold great potential in treating SCI, with specific roles, including immune modulation, anti-inflammatory effects, angiogenesis, apoptosis inhibition, and promotion of axonal regeneration, even surpassing traditional cell therapy in certain aspects. This paper aims to elucidate the potential mechanisms and valuable therapeutic roles of SCs and SC-exos in the treatment of SCI, as well as to provide insights for subsequent research directions by analyzing their current limitations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.